Medline Inc. IPO - What You Need to Know

Thinking about buying into the Medline IPO? It is a massive name in the medical world, and the official paperwork is finally here. Before you invest your hard-earned money, let’s break down the details in plain English.

1. What does this company actually do?

Think of Medline as the "Amazon of hospitals." If a healthcare provider needs surgical gloves, gowns, or bandages, Medline likely supplies them. They do not just act as a middleman; they manufacture many of the products they sell. They run a massive logistics network with 69 distribution centers and a fleet of over 2,000 delivery trucks to keep hospitals stocked.

They serve the entire healthcare system, including surgery centers, dental offices, and at-home care providers. With over 43,000 employees in more than 100 countries, they have grown their sales every year since they started.

2. The IPO Details: The "Need to Know"

As of late 2025, Medline has officially filed to go public. Here is the snapshot:

• Ticker Symbol: They plan to trade on the Nasdaq as “MDLN.”
• Price Range: They expect to sell shares at a midpoint of $28.00 each.
• Size: They plan to offer 179 million shares, aiming to raise about $5 billion.
• Use of Proceeds: The company will use this cash to pay down debt, fund potential acquisitions, and support daily operations.

3. How do they make money?

Medline uses a "Prime Vendor" model. They sign 5-year contracts to be a hospital's main supplier. Once they are in the door, they push their own Medline-branded products, which make up a large portion of their total sales.

A key strategy: They constantly work to switch hospitals from third-party brands to Medline’s own products. While Medline-branded items often have lower price tags, they are efficient to produce. By refining how they source materials and manage manufacturing, they keep costs low and profits steady as they grow.

4. Why do they win?

• Sticky Customers: Their contract retention rate is over 98%. Once a hospital signs on, they rarely leave, creating steady, predictable income.
• Innovation: They hold over 2,100 patents and launched 268 new products in the last three years. This helps them capture higher-profit segments of the market.
• Market Tailwinds: Healthcare spending in the U.S. has increased every year for 60 years. As the population ages, demand for medical supplies remains steady regardless of the economy.

5. Is the business healthy?

• The Numbers: For the first nine months of 2025, they brought in $20.6 billion in sales with a profit of $1 billion.
• Profitability: Their "Adjusted EBITDA" (a measure of core operating profit) was 12.9% for that period.
• Debt Profile: The company carries significant long-term debt from past acquisitions. A portion of the IPO money will go toward paying down this debt.

6. Who is running the show?

Medline is transitioning to new leadership, with 28-year veteran Jim Boyle taking the CEO role. However, the founding family remains committed, planning to buy up to $250 million worth of shares in this offering. It is usually a good sign when the founders keep "skin in the game."

7. What are the main risks?

• Competition: Giants like Cardinal Health and McKesson fight for market share. These rivals have deep pockets and could challenge Medline’s pricing.
• Hospital Budgets: If hospitals face financial pressure, they may demand lower prices. This could squeeze Medline's profit margins.
• International Growth: Only about 7% of their sales come from outside the U.S. This leaves them heavily exposed to domestic economic shifts.

Final Thoughts for Investors

IPOs can be like a rollercoaster on the first day. Prices often jump around because of the "hype." Before you jump in, ask yourself: Do I believe in this company's ability to remain the go-to supplier for hospitals over the next 5 years? If the answer is yes, the short-term volatility matters less than the long-term fundamentals.

Pro-tip: Before buying, search for the "S-1 filing" on the SEC’s EDGAR website. It is the official document that contains every detail about the company's risks and financials.

Disclaimer: I am an AI, not a financial advisor. Investing in IPOs carries significant risk. Always do your own research or talk to a professional before investing.